A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.

Study Overview

• Status: Not yet recruiting
• Conditions: Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
• Intervention / Treatment: Drug: HRS -8427; Drug: Imipenem and Cilastatin Sodium

• Study Type: Interventional
• Enrollment (Estimated): 126
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Xiaopeng Wang; Phone Number: +86-182-6038-7118; Email: xiaopeng.wang@hengrui.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Able and willing to provide a written informed consent before the study, fully understand the study and be able to complete the study according to the protocol;
2. Male and female, 18 to 75 years of age, inclusive;
3. Judged by the investigator, clinical diagnosis with cUTI or AP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics;
4. Urine specimen with evidence of pyuria；
5. Have urine culture specimen obtained within 48 hours prior to randomization;
6. Women of childbearing potential must have a negative serum pregnancy test before first dose, must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of contraception, with no plan of birth, sperm/ovum donation from the time of signed ICF till 14 days after end of treatment.

Exclusion Criteria:

1. History of significant hypersensitivity or allergic reaction to any β-lactam, or any β-lactamase inhibitors;
2. Known history of immune deficiency disease or receive immunocompromising treatment;
3. Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable condition or uncontrolled;
4. Known or suspected central nervous system disorder or other factors that may predispose to seizures or lower the seizures onset threshold;
5. Presence of any known or suspected disease or condition that, in the opinion of the Investigator, may confound the assessment of efficacy;
6. Uncomplicated lower urinary tract infection;
7. Suspected or confirmed urinary tract symptoms caused by acute/chronic prostatitis, orchitis, epididymitis or sexually transmitted diseases as determined by medical history and/or physical examination;
8. Patients diagnosed malignant tumors prior to randomization and currently with;
9. Systemic antimicrobial therapy other than the investigational drug need to be used during the study period, with the exception of topical or single oral dose of antifungal treatment
10. Urinary tract surgery prior to the randomization or urinary tract surgery planned during the study period;
11. Receipt of potentially effective systemic antibacterial therapy for a continuous duration of >24 hours during the previous 72 hours prior to the randomization;
12. History of pelvis or urinary tract trauma prior to the randomization;
13. Patients had severe trauma or received major surgery prior to the randomization, or surgery planned during the study period;
14. Impairment of renal function with estimated glomerular filtration rate <15 mL/min (calculated by the Modification of Diet in Renal Disease study equation);
15. Laboratory abnormalities in baseline specimens obtained at screening;
16. A QTcF interval prolongation at screening or abnormalities with clinical significance and may cause obvious safety risk to the subjects;
17. Known urine culture with at least one Gram-Negative uropathogen at ≥105 colony-forming units(CFU)/mL unsusceptible to Imipenem and Cilastatin Sodium, or only identify Gram-positive uropathogen, or confirmed fungal urinary tract infection with ≥103CFU/mL;
18. Indwelling catheter or urinary tract instrument, in the opinion of the Investigator, incapable of removal during the study period;
19. Likely to require the use of antibiotic for cUTI or AP prophylaxis after treatment;
20. Suspected of sepsis, producing life-threatening organ dysfunction;
21. Estimated survival within 6 weeks or rapidly progressive or end stage disease with high mortality rate;
22. Drug abuse prior to the randomization;
23. Participated in, any other clinical study involving the administration of active investigational or experimental medication prior to the randomization, or 5 half-lives, whichever is longer, prior to Screening;
24. In the judgment of the Investigator, other reasons unsuitable for study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group A：HRS-8427	Drug: HRS -8427; The dose and frequency of administration were adjusted according to the eGFR.
Experimental: Treatment group B：HRS-8427	Drug: HRS -8427; The dose and frequency of administration were adjusted according to the eGFR.
Active Comparator: Imipenem and Cilastatin Sodium	Drug: Imipenem and Cilastatin Sodium; The dose and frequency of administration were adjusted according to the eGFR .

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)	Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment（EA）、End of Treatment（EOT）and Late Follow-Up (LFU)	EA : Day 4、EOT: Day 7 to Day 14、LFU：Day 21 to Day 28
Percentage of Participants With Microbiological Eradication at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）	EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）
Percentage of Participants With Microbiological Eradication at EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen	EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen
Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）	EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）
Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen	EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2023
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): July 1, 2024

Study Registration Dates

• First Submitted: November 16, 2023
• First Submitted That Met QC Criteria: November 16, 2023
• First Posted (Actual): November 22, 2023

Study Record Updates

• Last Update Posted (Actual): November 22, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Kidney Diseases; Urologic Diseases; Disease Attributes; Nephritis; Nephritis, Interstitial; Pyelitis; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Infections; Communicable Diseases; Urinary Tract Infections; Pyelonephritis; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Protease Inhibitors; Anti-Bacterial Agents; Imipenem; Cilastatin; Cilastatin, Imipenem Drug Combination
• Other Study ID Numbers: HRS-8427-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No